Volume 91 Issue 9 | p. 23 | Concentrates
Issue Date: March 4, 2013

LEO Pharma, 4SC Ink Dermatology Deal

Department: Business
Keywords: licensing, drug discovery, dermatology

Leo Pharma, a Danish dermatology drug specialist, has signed a research and licensing agreement with Germany’s 4SC Discovery to research, develop, and commercialize an oral treatment for inflammatory skin disease. The partners say they are working on a compound in early-stage development that could significantly reduce symptoms of psoriasis. 4SC will receive $1.3 million in R&D financing and could get up to $125 million in milestone payments plus additional . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society